Need For Partnering Won’t Change But Shape Might - BioJapan
While industry participants at BioJapan expect big pharma to continue to seek external partnerships and acquisitions to bolster pipelines, the technology and countries involved in such alliances look set to change.
You may also be interested in...
Qpex licenses rights to its antibiotic portfolio in China to Brii Biosciences. Moberg and DongKoo partner on commercialization of onychomycosis therapy in Korea.
Roche's main consideration when partnering is to "access great science" regardless of location. More of this is expected to come out of Asia, its global partnering head tells Scrip.
The long-recurring theme of how effectively to foster Japan’s bioventure sector again emerged as a key thread at recent major industry meeting, while the broader topic of effective partnering occupied the minds of industry and academia alike.